Keynote Lecture: Erythropoietin and systemic hypertension
- 1 January 1995
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 10 (supp2) , 74-79
- https://doi.org/10.1093/ndt/10.supp2.74
Abstract
Systemic hypertension has been reported to develop, or to worsen, in 20–30% of patients treated with recombinant human erythropoietin (r-HuEPO) worldwide. The greatest increases in blood pressure affect day-time systolic and night-time diastolic blood pressure. Hypertension may develop in some patients as early as 2 weeks and in others as late as 4 months after the start of r-HuEPO treatment. In haemodialysis patients with systemic hypotension, r-HuEPO usually induces a 10% increase in blood pressure, with no significant change in the frequency of hypotensive episodes.Keywords
This publication has 0 references indexed in Scilit: